Literature DB >> 28843532

The medical threat of mamba envenoming in sub-Saharan Africa revealed by genus-wide analysis of venom composition, toxicity and antivenomics profiling of available antivenoms.

Stuart Ainsworth1, Daniel Petras2, Mikael Engmark3, Roderich D Süssmuth4, Gareth Whiteley1, Laura-Oana Albulescu1, Taline D Kazandjian1, Simon C Wagstaff5, Paul Rowley1, Wolfgang Wüster6, Pieter C Dorrestein7, Ana Silvia Arias8, José M Gutiérrez8, Robert A Harrison1, Nicholas R Casewell9, Juan J Calvete10.   

Abstract

Mambas (genus Dendroaspis) are among the most feared of the medically important elapid snakes found in sub-Saharan Africa, but many facets of their biology, including the diversity of venom composition, remain relatively understudied. Here, we present a reconstruction of mamba phylogeny, alongside genus-wide venom gland transcriptomic and high-resolution top-down venomic analyses. Whereas the green mambas, D. viridis, D. angusticeps, D. j. jamesoni and D. j. kaimosae, express 3FTx-predominant venoms, black mamba (D. polylepis) venom is dominated by dendrotoxins I and K. The divergent terrestrial ecology of D. polylepis compared to the arboreal niche occupied by all other mambas makes it plausible that this major difference in venom composition is due to dietary variation. The pattern of intrageneric venom variability across Dendroaspis represented a valuable opportunity to investigate, in a genus-wide context, the variant toxicity of the venom, and the degree of paraspecific cross-reactivity between antivenoms and mamba venoms. To this end, the immunological profiles of the five mamba venoms were assessed against a panel of commercial antivenoms generated for the sub-Saharan Africa market. This study provides a genus-wide overview of which available antivenoms may be more efficacious in neutralising human envenomings caused by mambas, irrespective of the species responsible. The information gathered in this study lays the foundations for rationalising the notably different potency and pharmacological profiles of Dendroaspis venoms at locus resolution. This understanding will allow selection and design of toxin immunogens with a view to generating a safer and more efficacious pan-specific antivenom against any mamba envenomation. BIOLOGICAL SIGNIFICANCE: The mambas (genus Dendroaspis) comprise five especially notorious medically important venomous snakes endemic to sub-Saharan Africa. Their highly potent venoms comprise a high diversity of pharmacologically active peptides, including extremely rapid-acting neurotoxins. Previous studies on mamba venoms have focused on the biochemical and pharmacological characterisation of their most relevant toxins to rationalize the common neurological and neuromuscular symptoms of envenomings caused by these species, but there has been little work on overall venom composition or comparisons between them. Only very recently an overview of the composition of the venom of two Dendroaspis species, D. angusticeps and D. polylepis, has been unveiled through venomics approaches. Here we present the first genus-wide transcriptomic-proteomic analysis of mamba venom composition. The transcriptomic analyses described in this paper have contributed 29 (D. polylepis), 23 (D. angusticeps), 40 (D. viridis), 25 (D. j. jamesoni) and 21 (D. j. kaimosae), novel full-length toxin sequences to the non-redundant Dendroaspis sequence database. The mamba genus-wide venomic analysis demonstrated that major D. polylepis venom components are Kunitz-fold family toxins. This feature is unique in relation to the relatively conserved three-finger toxin (3FTx)-dominated venom compositions of the green mambas. Venom variation was interpreted in the context of dietary variation due to the divergent terrestrial ecology of D. polylepis compared to the arboreal niche occupied by all other mambas. Additionally, the degree of cross-reactivity conservation of mamba venoms was assessed by antivenomics against a panel of commercial antivenoms generated for the sub-Saharan Africa market. This study provides a genus-wide overview to infer which available antivenoms may be capable of neutralising human envenomings caused by mambas, irrespective of the species responsible. The information gathered in this study lays the foundations for rationalising the pharmacological profiles of mamba venoms at locus resolution. This understanding will contribute to the generation of a safer and more efficacious pan-Dendroaspis therapeutic antivenom against any mamba envenomation.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Genus Dendroaspis; Genus-wide antivenomics; Mamba phylogeny reconstruction; Sub-Saharan antivenoms; Top-down snake venomics; Venom gland transcriptome; Venom toxicity

Mesh:

Substances:

Year:  2017        PMID: 28843532     DOI: 10.1016/j.jprot.2017.08.016

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  25 in total

1.  Adaptive evolution of distinct prey-specific toxin genes in rear-fanged snake venom.

Authors:  Cassandra M Modahl; Seth Frietze; Stephen P Mackessy
Journal:  Proc Biol Sci       Date:  2018-08-01       Impact factor: 5.349

Review 2.  Advances in venomics: Modern separation techniques and mass spectrometry.

Authors:  Tarek Mohamed Abd El-Aziz; Antonio G Soares; James D Stockand
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2020-09-17       Impact factor: 3.205

Review 3.  A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms.

Authors:  Kavi Ratanabanangkoon
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

4.  Anticoagulant Activity of Naja nigricollis Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib.

Authors:  Taline D Kazandjian; Arif Arrahman; Kristina B M Still; Govert W Somsen; Freek J Vonk; Nicholas R Casewell; Mark C Wilkinson; Jeroen Kool
Journal:  Toxins (Basel)       Date:  2021-04-23       Impact factor: 4.546

5.  Intact protein mass spectrometry reveals intraspecies variations in venom composition of a local population of Vipera kaznakovi in Northeastern Turkey.

Authors:  Daniel Petras; Benjamin-Florian Hempel; Bayram Göçmen; Mert Karis; Gareth Whiteley; Simon C Wagstaff; Paul Heiss; Nicholas R Casewell; Ayse Nalbantsoy; Roderich D Süssmuth
Journal:  J Proteomics       Date:  2019-02-11       Impact factor: 3.855

6.  Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa.

Authors:  Robert A Harrison; George O Oluoch; Stuart Ainsworth; Jaffer Alsolaiss; Fiona Bolton; Ana-Silvia Arias; José-María Gutiérrez; Paul Rowley; Stephen Kalya; Hastings Ozwara; Nicholas R Casewell
Journal:  PLoS Negl Trop Dis       Date:  2017-10-18

7.  Protein Identification of Venoms of the African Spitting Cobras, Naja mossambica and Naja nigricincta nigricincta.

Authors:  Ottilie Katali; Loide Shipingana; Peter Nyarangó; Mirva Pääkkönen; Erastus Haindongo; Timothy Rennie; Peter James; John Eriksson; Christian John Hunter
Journal:  Toxins (Basel)       Date:  2020-08-14       Impact factor: 4.546

Review 8.  Antibody Cross-Reactivity in Antivenom Research.

Authors:  Line Ledsgaard; Timothy P Jenkins; Kristian Davidsen; Kamille Elvstrøm Krause; Andrea Martos-Esteban; Mikael Engmark; Mikael Rørdam Andersen; Ole Lund; Andreas Hougaard Laustsen
Journal:  Toxins (Basel)       Date:  2018-09-27       Impact factor: 4.546

Review 9.  Snake Venom Peptides: Tools of Biodiscovery.

Authors:  Aisha Munawar; Syed Abid Ali; Ahmed Akrem; Christian Betzel
Journal:  Toxins (Basel)       Date:  2018-11-14       Impact factor: 4.546

10.  Convergent evolution of pain-inducing defensive venom components in spitting cobras.

Authors:  T D Kazandjian; D Petras; S D Robinson; J van Thiel; H W Greene; K Arbuckle; A Barlow; D A Carter; R M Wouters; G Whiteley; S C Wagstaff; A S Arias; L-O Albulescu; A Plettenberg Laing; C Hall; A Heap; S Penrhyn-Lowe; C V McCabe; S Ainsworth; R R da Silva; P C Dorrestein; M K Richardson; J M Gutiérrez; J J Calvete; R A Harrison; I Vetter; E A B Undheim; W Wüster; N R Casewell
Journal:  Science       Date:  2021-01-22       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.